Blueprint Medicines Reports Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St up after tech selloff as yields retreat; Moderna surges
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Target raises full-year sales forecast amid ongoing turnaround drive
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Francisco Partners to acquire Weave Communications for $650M
Blueprint Medicines (BPMC) Misses Q2 EPS by 13c, Revenues Beat
August 1, 2019 7:23 AM EDTBlueprint Medicines (NASDAQ: BPMC) reported Q2 EPS of ($2.04), $0.13 worse than the analyst estimate of ($1.91). Revenue for the quarter came in at $5.11 million versus the consensus estimate of $1.98 million.
Second Quarter 2019 Financial Results:
Cash Position: As of June 30, 2019, cash, cash equivalents and investments were $667.3 million, as compared to $494.0 million as of December 31, 2018. This increase reflects net proceeds of approximately $327.4 million from the company's follow-on underwritten public offering of common stock, which closed in April 2019, partially offset by cash used in operations.Collaboration Revenues: Collaboration revenues were $5.1 million for the second quarter... More